Main Conference Days

8.00 am Check In & Morning Coffee

8:50 am Chair’s Opening Remarks

  • Kinkini Roy Associate Director – Drug Product Development , Aviceda Therapeutics

Showcasing State-of-the-Art Peptide-Based Therapeutic Delivery Technologies to Accelerate Peptide Drugs Towards Patients

9:00 am Bio-Inspired Oral Drug Delivery Platforms for Biological Therapeutics

  • Yuhan Lee Co-Founder & Assistant Professor, AltrixBio & Harvard Medical School

Synopsis

  • Designing cutting-edge robotic devices for targeted peptide drug delivery
  • Discussing underlying mechanisms of oral administration through the GI tissue to maximize the bioavailability
  • Improving peptide bioavailability, increasing absorption and enabling high- dose peptide delivery

9:30 am Long-Acting Nanoformulation for the Delivery of Fusion Inhibitor Peptide & Small Molecule

  • Dhanashree Surve Assistant Scientist, University of Miami Miller School of Medicine

Synopsis

  • Considerations of physicochemical properties of the drugs and peptide for designing a long-acting combination drug delivery platform
  • Unveiling how the site of injection/administration drives the pharmacokinetics of longacting formulations
  • Showcasing how the drug delivery strategy is predetermined based on the immune cell target

10:00 am Peptide Modification for Targeted Delivery

  • Kinkini Roy Associate Director – Drug Product Development , Aviceda Therapeutics

Synopsis

  • Selecting appropriate peptides for targeted delivery
  • Ensuring bioconjugation efficiency
  • Investigating the stability of peptides in the blood stream

10:30 am Morning Refreshments, Networking Break & Poster Session

11:30 am A Novel Safe & Re-Dosable Peptide-Based Nanoparticle Platform for Targeted Delivery

  • Gilles Divita Co-Founder & Chief Executive Officer, Divincell / Aanastra

Synopsis

  • Designing and using AI-driven optimization of a peptide-vector for cell membrane selectivity and cellular uptake
  • Defining safety and characterization of peptide-based nanoparticles for extrahepatic delivery of different payloads including peptide, protein and RNA
  • Applying a peptide-based nanoparticle platform for systemic targeted delivery of therapeutic mRNA: T cell engineering and tumor selectivity

12:00 pm Microsphere Delivery Systems for Controlling the Release of Proteins & Peptides

  • Ankur Sharma Senior Formulation & Development Scientist, Hyalo Technologies

Synopsis

  • Examining how microspheres are developed
  • Revealing various types of microspheres
  • Controlling peptide drug product release and maintaining stability

12.30 pm Lunch & Networking Break

Pushing the Limits of Peptide Formulation Through Different Modes of Administration to Maximize Pan-Disease Applications

1:30 pm Harnessing Polymeric Nanoparticle Technologies for Intradermal Peptide Delivery

  • Mike Davies Founder & Chief Executive Officer , Carocell Bio

Synopsis

  • Applying nanoparticle delivery of peptides in atopic dermatitis with a polymer with antistaphylococcal activity that does not disturb dermal cell membranes
  • Sharing skin biopsy data that demonstrates how leveraging nanoparticle transfection agents to deliver peptides into dermal cells is faster and more effective, compared to topical steroids
  • Enabling microdose peptide delivery and discussing the safety aspect of topical peptide applications

2:00 pm Enhancing Bioavailability of Peptide Drugs for Nasal Delivery

Synopsis

  • Providing an overview of the opportunities and challenges of nasal drug delivery
  • Overcoming some of the key challenges to nasal delivery through the use of absorption enhancers
  • Discussing considerations of formulation aspects of nasal drug development
  • Making considerations for translational aspects of nasal drug product development
  • Demonstrating human and animal data examples of improvements in bioavailability for small molecules and nose to brain delivery for peptides using an absorption enhancer

2:30 pm Next-Generation Nasal & Inhalation Delivery of Peptides: Enhancing Stability & Barrier Penetration

  • Nitin Joshi Assistant Professor , Brigham & Women’s Hospital, Harvard Medical School

Synopsis

  • Overcoming challenges of localized inhalation and nasal delivery to the lungs and to the brain, respectively
  • Highlighting next-generation encapsulation techniques to stabilize peptides for delivery without any chemical conjugation
  • Crossing mucosal, epithelial and cellular barriers

3.00 pm Afternoon Networking Break

Harnessing Cross-Learnings From GLP-1 Targeted Therapies & Peptide-Based Drugs in Clinical Stages of Development to Optimize Target Product Profiles

3:30 pm Showcasing Risperidone as an Oral Weekly, as Opposed to Oral Daily Capsule for the Treatment of Schizophrenia

  • Rose Kanasty Vice President of Platform Development, Lyndra Therapeutics

Synopsis

Details to be released

4:00 pm Considerations for Development & Commercialization of Peptide Products

  • Peter Knauer Vice President of CMC , Xeris Pharmaceuticals

Synopsis

  • Managing the evolution of dosage forms from early to late-stage development
  • Understanding the implications of chemical and physical stability throughout the development program
  • Evolving a target product profile (TPP) through the development program
  • Using a novel formulation platform to achieve better TPP

4:30 pm Chair’s Closing Remarks & End of Summit

  • Kinkini Roy Associate Director – Drug Product Development , Aviceda Therapeutics